Related references
Note: Only part of the references are listed.Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (P1CC): a single-centre, parallel-group, noncomparative, randomised, phase 2 trial
Huabin Hu et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Nanoscale Diamond-Based Formulation as an Immunomodulator and Potential Therapeutic for Lymphoma
Ankush Paladhi et al.
FRONTIERS IN PHARMACOLOGY (2022)
Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response
Yosuke Sato et al.
BMC CANCER (2021)
Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
Vidhi Khanna et al.
SCIENTIFIC REPORTS (2021)
Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts
Nathalia D. de Moura Sperotto et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review
Yong Li et al.
FRONTIERS IN ONCOLOGY (2021)
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
Per Pfeiffer et al.
LANCET ONCOLOGY (2020)
Leishmanicidal Activity of an In Silico-Screened Novel Inhibitor against Ascorbate Peroxidase of Leishmania donovani
Mohammad Kashif et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Galunisertib Drives Treg Fragility and Promotes Dendritic Cell-Mediated Immunity against Experimental Lymphoma
Sumit Kumar Hira et al.
ISCIENCE (2020)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (vol 8, e000337, 2020)
Lorenzo Galluzzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Immunotherapy in colorectal cancer: rationale, challenges and potential
Karuna Ganesh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
Mauro Di Pilato et al.
NATURE (2019)
Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results
Beatris Mastelic-Gavillet et al.
FRONTIERS IN IMMUNOLOGY (2019)
Engineering dendritic cell vaccines to improve cancer immunotherapy
Caleb R. Perez et al.
NATURE COMMUNICATIONS (2019)
Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages
Emeric Limagne et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Necroptosis of tumor cells leads to tumor necrosis and promotes tumor metastasis
Delong Jiao et al.
CELL RESEARCH (2018)
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
Marco Tampellini et al.
FUTURE ONCOLOGY (2018)
Thymidine phosphorylase: A potential new target for treating cardiovascular disease
Wei Li et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2018)
Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression
Kazuaki Matsuoka et al.
Oncotarget (2018)
Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications
Jessica Roelands et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
James M. Cleary et al.
INVESTIGATIONAL NEW DRUGS (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Thymidine Catabolism as a Metabolic Strategy for Cancer Survival
Sho Tabata et al.
CELL REPORTS (2017)
Protease-Responsive Targeted Delivery of Doxorubicin from Bilirubin-BSA-Capped Mesoporous Silica Nanoparticles against Colon Cancer
Prateek Srivastava et al.
ACS BIOMATERIALS SCIENCE & ENGINEERING (2017)
Protease-Responsive Targeted Delivery of Doxorubicin from Bilirubin-BSA-Capped Mesoporous Silica Nanoparticles against Colon Cancer
Prateek Srivastava et al.
ACS BIOMATERIALS SCIENCE & ENGINEERING (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis
Craig M. Brackett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Dendritic cell-based cancer immunotherapy for colorectal cancer
Mikio Kajihara et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Roy L. Maute et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
John C. Castle et al.
BMC GENOMICS (2014)
Downregulation of endogenous STAT3 augments tumoricidal activity of interleukin 15 activated dendritic cell against lymphoma and leukemia via TRAIL
Sumit Kumar Hira et al.
EXPERIMENTAL CELL RESEARCH (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer
Elinor Bexe Lindskog et al.
BMC CLINICAL PATHOLOGY (2014)
Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
Melissa G. Lechner et al.
JOURNAL OF IMMUNOTHERAPY (2013)
TAS-102: more than an antimetabolite
Godefridus J. Peters et al.
LANCET ONCOLOGY (2012)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino et al.
LANCET ONCOLOGY (2012)
Thymidine Phosphorylase Gene Expression in Stage III Colorectal Cancer
Elinor B. Lindskog et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2012)
Adoptive immunotherapy for cancer: harnessing the T cell response
Nicholas P. Restifo et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Natural Killer Cells and Solid Tumors
Ana Stojanovic et al.
JOURNAL OF INNATE IMMUNITY (2011)
Plasticity of CD4+ T Cell Lineage Differentiation
Liang Zhou et al.
IMMUNITY (2009)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
The role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior
I. V. Bijnsdorp et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2008)
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment
Anuradha Budhu et al.
CANCER CELL (2006)
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment
M Toi et al.
LANCET ONCOLOGY (2005)
Share Paper
